Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy vTv Therapeutics stock

Learn how to easily invest in vTv Therapeutics stock.

vTv Therapeutics Inc is a biotechnology business based in the US. vTv Therapeutics shares (VTVT) are listed on the NASDAQ and all prices are listed in US Dollars. vTv Therapeutics employs 9 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in vTv Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VTVT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

vTv Therapeutics stock price (NASDAQ: VTVT)

Use our graph to track the performance of VTVT stocks over time.

vTv Therapeutics shares at a glance

Information last updated 2022-07-02.
Latest market close$0.72
52-week range$0.38 - $2.27
50-day moving average $0.63
200-day moving average $0.96
Wall St. target price$4.17
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.25

Buy vTv Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you open a Robinhood account
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy vTv Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

vTv Therapeutics price performance over time

Historical closes compared with the close of $0.72 from 2022-07-01

1 week (2022-06-28) -5.30%
1 month (2022-06-03) 1.41%
3 months (2022-04-01) N/A
6 months (2022-01-04) -28.00%
1 year (2021-07-02) -67.57%
2 years (2020-07-02) -68.28%
3 years (2019-07-05) 1.43
5 years (2017-07-05) 5.17

vTv Therapeutics financials

Revenue TTM $5 million
Gross profit TTM $-8,619,000
Return on assets TTM -75.34%
Return on equity TTM -335.49%
Profit margin 0%
Book value $-1.67
Market capitalisation $55.7 million

TTM: trailing 12 months

vTv Therapeutics share dividends

We're not expecting vTv Therapeutics to pay a dividend over the next 12 months.

vTv Therapeutics share price volatility

Over the last 12 months, vTv Therapeutics's shares have ranged in value from as little as $0.382 up to $2.27. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while vTv Therapeutics's is -1.4043. This would suggest that vTv Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, vTv Therapeutics has bucked the trend.

vTv Therapeutics overview

vTv Therapeutics Inc. , a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc.

Frequently asked questions

What percentage of vTv Therapeutics is owned by insiders or institutions?
Currently 70.336% of vTv Therapeutics shares are held by insiders and 7.796% by institutions.
How many people work for vTv Therapeutics?
Latest data suggests 9 work at vTv Therapeutics.
When does the fiscal year end for vTv Therapeutics?
vTv Therapeutics's fiscal year ends in December.
Where is vTv Therapeutics based?
vTv Therapeutics's address is: 3980 Premier Drive, High Point, NC, United States, 27265
What is vTv Therapeutics's ISIN number?
vTv Therapeutics's international securities identification number is: US9183851057
What is vTv Therapeutics's CUSIP number?
vTv Therapeutics's Committee on Uniform Securities Identification Procedures number is: 918385105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site